{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hydrogen&page=2",
    "query": {
      "intervention": "Hydrogen",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hydrogen&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-15T00:28:25.756Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02020707",
      "title": "Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cervical Adenocarcinoma",
        "Cervical Adenosarcoma",
        "Cervical Adenosquamous Carcinoma",
        "Cervical Carcinosarcoma",
        "Cervical Squamous Cell Carcinoma",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Endometrial Adenosquamous Carcinoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrial Endometrioid Adenocarcinoma",
        "Endometrial Mixed Cell Adenocarcinoma",
        "Endometrial Mucinous Adenocarcinoma",
        "Endometrial Serous Adenocarcinoma",
        "Endometrial Undifferentiated Carcinoma",
        "Fallopian Tube Adenocarcinoma",
        "Fallopian Tube Carcinosarcoma",
        "Fallopian Tube Clear Cell Adenocarcinoma",
        "Fallopian Tube Endometrioid Adenocarcinoma",
        "Fallopian Tube Mucinous Adenocarcinoma",
        "Fallopian Tube Serous Adenocarcinoma",
        "Fallopian Tube Squamous Cell Carcinoma",
        "Fallopian Tube Transitional Cell Carcinoma",
        "Fallopian Tube Undifferentiated Carcinoma",
        "Malignant Female Reproductive System Neoplasm",
        "Malignant Ovarian Clear Cell Tumor",
        "Malignant Ovarian Endometrioid Tumor",
        "Malignant Ovarian Epithelial Tumor",
        "Malignant Ovarian Mucinous Tumor",
        "Malignant Peritoneal Neoplasm",
        "Malignant Solid Neoplasm",
        "Ovarian Carcinosarcoma",
        "Ovarian Clear Cell Adenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian High Grade Serous Adenocarcinoma",
        "Ovarian Mucinous Adenocarcinoma",
        "Ovarian Serous Adenocarcinoma",
        "Ovarian Transitional Cell Carcinoma",
        "Ovarian Undifferentiated Carcinoma",
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Ovarian Carcinoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Platinum-Sensitive Ovarian Carcinoma",
        "Primary Peritoneal Carcinosarcoma",
        "Primary Peritoneal Clear Cell Adenocarcinoma",
        "Primary Peritoneal Serous Adenocarcinoma",
        "Primary Peritoneal Transitional Cell Carcinoma",
        "Primary Peritoneal Undifferentiated Carcinoma",
        "Unresectable Melanoma",
        "Uterine Corpus Carcinosarcoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2014-02-24",
      "completion_date": "2024-07-18",
      "has_results": false,
      "last_update_posted_date": "2024-07-26",
      "last_synced_at": "2026-09-15T00:28:25.756Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02020707"
    },
    {
      "nct_id": "NCT01681095",
      "title": "Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Myocardial Ischemia",
        "Coronary Disease",
        "Heart Diseases",
        "Valvular Heart Disease"
      ],
      "interventions": [
        {
          "name": "Custodiol HTK",
          "type": "DRUG"
        },
        {
          "name": "Cold Blood Cardioplegia",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marc Sakwa, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2012-08",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2019-08-06",
      "last_synced_at": "2026-09-15T00:28:25.756Z",
      "location_count": 1,
      "location_summary": "Royal Oak, Michigan",
      "locations": [
        {
          "city": "Royal Oak",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01681095"
    },
    {
      "nct_id": "NCT03038672",
      "title": "Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ALK-Positive Large B-Cell Lymphoma",
        "Diffuse Large B-Cell Lymphoma Activated B-Cell Type",
        "Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation",
        "Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type",
        "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "EBV-Positive Mucocutaneous Ulcer",
        "HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Intravascular Large B-Cell Lymphoma",
        "Large B-Cell Lymphoma With 11q Aberration",
        "Large B-Cell Lymphoma With IRF4 Rearrangement",
        "Plasmablastic Lymphoma",
        "Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System",
        "Primary Effusion Lymphoma",
        "Recurrent B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Burkitt Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Gray-Zone Lymphoma",
        "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Recurrent Lymphomatoid Granulomatosis",
        "Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type",
        "Recurrent Primary Mediastinal Large B-Cell Lymphoma",
        "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma",
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "Refractory Burkitt Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Gray-Zone Lymphoma",
        "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type",
        "Refractory Primary Mediastinal Large B-Cell Lymphoma",
        "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varlilumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2018-12-21",
      "completion_date": "2026-10-24",
      "has_results": true,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-09-15T00:28:25.756Z",
      "location_count": 33,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03038672"
    },
    {
      "nct_id": "NCT03005002",
      "title": "Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Carcinoma in the Liver",
        "MLH1 Gene Mutation",
        "MSH6 Gene Mutation",
        "PMS2 Gene Mutation",
        "Stage IV Colorectal Cancer",
        "Stage IVA Colorectal Cancer",
        "Stage IVB Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Tremelimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2017-06-28",
      "completion_date": "2019-11-26",
      "has_results": false,
      "last_update_posted_date": "2019-12-26",
      "last_synced_at": "2026-09-15T00:28:25.756Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03005002"
    },
    {
      "nct_id": "NCT04603794",
      "title": "Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "0.5% Povidone Iodine",
          "type": "DRUG"
        },
        {
          "name": "0.12% Chlorhexidine Gluconate Mouth Rinse",
          "type": "DRUG"
        },
        {
          "name": "1% Hydrogen Peroxide",
          "type": "DRUG"
        },
        {
          "name": "0.9% Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2020-10-01",
      "completion_date": "2020-11",
      "has_results": false,
      "last_update_posted_date": "2020-10-27",
      "last_synced_at": "2026-09-15T00:28:25.756Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04603794"
    },
    {
      "nct_id": "NCT05001880",
      "title": "Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peritoneal Malignant Mesothelioma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cytoreductive Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Hyperthermic Intraperitoneal Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2022-03-22",
      "completion_date": "2027-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-09-15T00:28:25.756Z",
      "location_count": 40,
      "location_summary": "Phoenix, Arizona • Chicago, Illinois • Danville, Illinois + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Danville",
          "state": "Illinois"
        },
        {
          "city": "Effingham",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05001880"
    },
    {
      "nct_id": "NCT05455697",
      "title": "Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma",
        "Grade 3b Follicular Lymphoma",
        "High Grade B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Retifanlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rituximab and Hyaluronidase Human",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tafasitamab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "OTHER"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Polatuzumab Vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2023-01-26",
      "completion_date": "2027-01-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-09-15T00:28:25.756Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05455697"
    },
    {
      "nct_id": "NCT01318577",
      "title": "Study of A New Contact Lens Cleaning and Disinfecting Solution",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Vision Disorders"
      ],
      "interventions": [
        {
          "name": "Investigational Cleaning & Disinfecting Solution",
          "type": "DEVICE"
        },
        {
          "name": "Clear Care Solution",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 444,
      "start_date": "2010-11",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2020-10-08",
      "last_synced_at": "2026-09-15T00:28:25.756Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01318577"
    },
    {
      "nct_id": "NCT00324987",
      "title": "Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastrointestinal Stromal Tumor"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Imatinib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2008-04",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2017-09-14",
      "last_synced_at": "2026-09-15T00:28:25.756Z",
      "location_count": 190,
      "location_summary": "Berkeley, California • Burlingame, California • Greenbrae, California + 122 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Burlingame",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Novato",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00324987"
    },
    {
      "nct_id": "NCT03132532",
      "title": "Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Stage II Lung Cancer AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Unresectable Lung Non-Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Proton Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-07-31",
      "completion_date": "2023-12-23",
      "has_results": true,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-09-15T00:28:25.756Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03132532"
    }
  ]
}